In conclusion, these data suggest that targeting of CaSR with NPS-2143 in AML in combination with standard chemotherapy may be superior to chemotherapy alone, though the numbers of tested human AML samples are small. The gene discussed is CASR; the disease is acute myeloid leukemia.